Immune Cells of the Brain Renew Hopes for Curing Alzheimer’s Disease

A brand new experimental study executed in mice demonstrates microglia, immune cells from the brain, might play a key role in protecting the brain from Alzheimer’s disease (AD). It’s long considered that toxic sticky protein deposits from the brain called amyloid beta (Aβ) have the effect of forgetfulness in AD patients.

Diabetes Drug Improve Memory and Learning in Patients with Alzheimer’s Disease

An FDA approved diabetes drug could improve cognitive performance in patients suffering from Alzheimer’s disease. This study was conducted on genetically engineered mice designed to serve as models for Alzheimer’s at University of Texas Medical Branch at Galveston to determine the effect of anti-insulin resistant drug rosiglitazone on memory and learning.

Long Term Use Of Pills For Anxiety And Sleep Problems May Be Linked to Alzheimer’s

Bottom Line: Taking benzodiazepines (widely prescribed drugs to treat anxiety and insomnia) is associated with an increased risk of developing Alzheimer’s disease, particularly for long-term users, suggests a study published on the bmj.com today. Full Study: The researchers warn that unwarranted long-term use should be considered a public health concern. Dementia currently affects about 36 million … Continue reading Long Term Use Of Pills For Anxiety And Sleep Problems May Be Linked to Alzheimer’s

Leuven Research Opens New Pathway to Treat Alzheimer’s Disease

Scientists from VIB and KU Leuven realize a fresh target molecule for the development of a treatment against Alzheimer’s disease. There is currently no cure for this disease. Many candidate drugs fail because they also target proteins required to life. This discovery from Leuven could form a target for any treatment against Alzheimer’s disease with … Continue reading Leuven Research Opens New Pathway to Treat Alzheimer’s Disease

Gene Nearly Triples Risk of Alzheimer’s Identified

International teams of researchers from Mayo Clinic have discovered a gene that could triple the risk of Alzheimer’s disease, according to the latest study published in online edition of the New England Journal of Medicine (NEJM).  It is considered as the most potent genetic factor for Alzheimer’s disease that has been identified since 20 years.

New Drug Of Lilly May Slow Memory Loss in Mild Alzheimer’s

New Alzheimer’s drug could reduce memory decline upto 34% in patients of mild symptoms over a period of 18 months as announced by Eli Lilly and Co.In august it was said by Lilly that its drug solanezumab did not achieve primary goal of “halting progression of the memory-robbing disease in patients with mild-to-moderate symptoms in … Continue reading New Drug Of Lilly May Slow Memory Loss in Mild Alzheimer’s